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ReviewThe Roles of the New Negative
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in Regulating Autoimmunity
proteins with IgV and IgC extracellular domains for the
ligands but only an IgV domain for the receptors. While
CD28 is expressed by both resting and activated T cells,
CTLA-4 is expressed only on activated T cells. Because
CTLA-4 binds B7 molecules with a higher affinity than
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does CD28, its inhibitory interaction eventually predomi-
nates, leading to the termination of the immune re-
sponse (Walunas et al., 1994). The importance of CTLA-4The B7 family of T cell costimulatory molecules has
as a negative regulatory T cell costimulatory moleculerecently acquired several new members. Some of
in the physiologic termination of T cell responses isthese are activating while others are inhibitory. In this
highlighted by the observation that CTLA-4 gene knock-review, we will focus on the novel inhibitory pathways
out mice develop massive lymphoproliferation and earlywith particular emphasis on the PD-1:PD-L pathway.
death (Tivol et al., 1995; Waterhouse et al., 1995). It hasUnderstanding the mechanisms of these pathways
even been suggested that CTLA-4 may function as ahas implications for development of novel treatment
master switch, playing a key role in peripheral tolerancestrategies for autoimmune disease, transplantation,
(Bluestone, 1997). Indeed, in several animal modelstumor immunotherapy, and vaccine development.
blockade of CTLA-4 signaling results in exacerbation of
autoimmune diseases (Chitnis et al., 2001; KarandikarIntroduction
et al., 1996; Luhder et al., 1998). The exact molecular
mechanisms of CTLA-4 regulation are complex and haveThe immune system has developed powerful mecha-
been recently reviewed (Baroja and Madrenas, 2003;nisms to prevent unnecessary activation of T cells and
Rothstein and Sayegh, 2003).thus autoimmunity (Van Parijs and Abbas, 1998); one
In humans, several reports established an associationsuch mechanism is the intricate balance between posi-
between specific genetic polymorphisms of the CTLA-4tive and negative costimulatory signals delivered to
gene and autoimmune disease. The potential explana-T cells after antigenic encounter (Rothstein and Sayegh,
tion is that such genetic polymorphisms may affect the2003). These second signals are dependent on the inter-
expression and/or function of the CTLA-4 receptor, thusaction of cell surface receptors with their ligands, typi-
resulting in autoreactivity. A single nucleotide polymor-cally on antigen-presenting cells (APCs), that provide
phism (SNP) in the 6.1 kb 3 region of CTLA-4 was re-essential costimulatory signals complimentary to those
ported to be associated with disease risk in Grave’sprovided by the TCR (signal 1). Positive costimulatory
disease, autoimmune hypothyroidism, and type 1 diabe-signals are pivotal in determining whether recognition
tes (Ueda et al., 2003). Furthermore, the expression ofof antigen by T cells leads to full T cell activation or to
the human CTLA-4 mRNA isoforms (full-length CTLA-4anergy/death. In addition, recent findings indicate that
and soluble CTLA-4) correlated with the genotype (Uedaregulation of immune responses may be achieved by
et al., 2003). Soluble CTLA-4 is known to be translated,the expression of inhibitory costimulatory molecules on
secreted, and present in human serum (Magistrelli et al.,APCs and peripheral tissues that mediate negative
1999; Oaks et al., 2000). A CTLA-4 gene polymorphismcostimulatory signals to the T cell. Therefore, the ulti-
located in the 3 untranslated region was also reportedmate fate of T cells and in turn immune responses ap-
to be associated with rheumatoid arthritis in Spanishpears to be mediated, at least in part, by the interplay
patients (Rodriguez et al., 2002). CTLA-4 gene polymor-
between positive and negative T cell costimulatory path-
phisms were also associated with susceptibility to multi-
ways (Rothstein and Sayegh, 2003).
ple sclerosis (Kantarci et al., 2003). Interestingly, in the
The best-studied costimulatory pathway is the CD28/ mouse a splice variant of CTLA-4 that encodes a trans-
CTLA-4-CD80/CD86 pathway (Coyle and Gutierrez- membrane isoform of CTLA-4 with the CD80/CD86 bind-
Ramos, 2001; Rothstein and Sayegh, 2003; Sharpe and ing domain missing (ligand-independent isoform) is as-
Freeman, 2002). This complex pathway serves as the sociated with exon 2 SNP. The liCTLA-4 transcript is
prototype costimulatory pathway, where the B7 ligands formed by skipping exon 2 and has a 4-fold increase in
(CD80/B7-1 and CD86/B7-2) bind to both an activating expression in both activated and resting spleen cells
(CD28) and an inhibitory (CTLA-4) receptor on T cells. from the diabetes-resistant strain as compared with the
They are members of the B7:CD28 family (Carreno and autoimmune-prone NOD strain (Ueda et al., 2003). Tar-
Collins, 2002), whose other members also include geting CTLA-4 for therapeutic purposes has been more
PD-1:PD-L pathway, ICOS-ICOSL pathway, unknown frustrating (Baroja and Madrenas, 2003); as one ap-
receptor-B7H4 (BTLA has been proposed as the recep- proach, CTLA-4-specific single chain Ab was developed
tor for B7H4 based on the binding of B7H4Ig to wild- and expressed on the cell surface to promote selective
type, but not BTLA/, cells), and unknown receptor- engagement of this regulatory molecule (Griffin et al.,
B7H3 (Rietz and Chen, 2004; Rothstein and Sayegh, 2000, 2001). This antibody attenuated T cell responses
2003). The members of this family are transmembrane only when coengaged with the TCR during T cell:APC
interaction, but this approach has not been tested in a
disease model in vivo. In addition, recent data indicate*Correspondence: skhoury@rics.bwh.harvard.edu (S.J.K.); msayegh@
rics.bwh.harvard.edu (M.H.S.) that some immunomodulatory strategies may induce
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Figure 1. Schematic Representation of the B7 Family of Costimulatory Molecules Expressed on T Cells and APCs, with a Focus on the
Inhibitory Pathways
Since some of the interactions involve ligation of alternate receptors, the outcome of the receptor ligation is shown as arrows on the right
with the white arrows representing activating signals, while the red arrows represent inhibitory signals.
tolerance by upregulation of CTLA-4 (Ariyan et al., 2003; of transplantation, infectious diseases, asthma/allergy,
and cancer.Fecteau et al., 2001).
In this review we will highlight the role of the newly
discovered negative T cell costimulatory pathways (Fig- The PD-1 Pathway
PD-1 and Its Ligandsures 1 and 2) in regulating autoimmunity with the goal
of future development of novel therapeutic strategies to The PD-1 (programmed death-1) receptor was initially
described in cell lines undergoing programmed cellreestablish tolerance in human autoimmune disease and
to regulate unwanted immune responses in the setting death by subtractive hybridization technique (Ishida et
Figure 2. Schematic Representation of the
Negative T Cell Costimulatory Molecules Ex-
pressed on T Cells and Parenchymal Cells
Interaction of receptors on activated autore-
active T cells with their corresponding ligands
on parenchymal cells leads to termination of
T cell responses protecting tissues from au-
toimmune destruction. Under certain circum-
stances (e.g., constitutive expression), inter-
action of the ligands with alternate receptors
delivers a positive signal that worsens local
autoimmune destruction.
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al., 1992) and was thought to be involved in the pro- latory CD4CD25 T cells, but whether it plays a role in
functional regulation mediated by these cells remainsgrammed death pathway, hence its name. Later, it was
demonstrated that PD-1 expression is induced by T and unknown (Baecher-Allan et al., 2001).
There are also data suggesting the existence of an-B cell activation (Agata et al., 1996). It is a transmem-
brane protein of the Ig superfamily, and similar to other receptor that binds PD-L1 and PD-L2; mutants of
PD-L1 and PD-L2, which lose their ability to bind PD-1,CTLA-4 it possesses only a single V-like domain and an
immunoreceptor tyrosine-based inhibiting motif (ITIM) remain costimulatory for T cells (Shin et al., 2003; Wang
et al., 2003). In addition, tumor cells express PD-L1 andwithin its cytoplasmatic tail. PD-1 shares 23% homology
with CTLA-4, but it lacks the MYPPPY motif required enhance killing of antigen-specific T cells through recep-
tors other than PD-1, providing a potential mechanismfor B7-1 and B7-2 binding (Agata et al., 1996). Thus,
PD-1 does not bind to either CD80 or CD86. PD-1 lacks for how cancerous cells evade tumor immunity (Dong
and Chen, 2003; Dong et al., 2002). These alternativethe cysteine (Cys) residue that allows other family mem-
bers to homodimerize, so unlike CTLA-4, PD-1 is a mono- receptor/s have not been identified as of yet.
PD-1 Signaling and T Cell Responsesmer both on the cell surface and in solution (Zhang et
al., 2004). CTLA-4 forms homodimers that bridge biva- Activation of human T cells by anti-CD3 is inhibited by
PD-L1 engagement of PD-1 on T cells (Freeman et al.,lent B7-1 homodimers in a zipper-like oligomerization
that provides the structural basis for forming unusually 2000). In addition, PD-L-1:PD-1 interactions can coun-
terbalance CD3-mediated activation when CD28-medi-stable signaling complexes at the T cell surface (Stamper
et al., 2001), underscoring the importance of potent in- ated costimulation is suboptimal (Freeman et al., 2000).
PD-1 expression on activated T cells is highest with ahibitory signaling in human immune responses. The
presence of the ITIM in the cytoplasmic tail suggests weak TCR signal, so that weakly activated T cells are
most readily downregulated by PD-L engagement (Free-that it could serve to inhibit the immune response (Ra-
vetch and Lanier, 2000). A second tyrosine residue re- man et al., 2000). Recent gene chip analyses have dem-
onstrated that PD-1 mRNA is highly expressed insides in a newly described variant called immunorecep-
tor tyrosine-based switch motif (ITSM) (Shlapatska et CD4CD25 regulatory T cells and anergic T cells, sug-
gesting several means by which PD-1 may be involvedal., 2001); the inhibitory activity of PD-1 is dependent
on association of the cytoplasmic tyrosine phosphatase in regulating T cell tolerance (Gavin et al., 2002; Lechner
et al., 2001). Engagement of PD-1 by PD-L2 also inhibitsSHP-2 with the ITSM rather than the ITIM motif that is
more typically associated with inhibitory signals (Latch- T cell TCR-mediated proliferation and cytokine produc-
tion by CD4 T cells (Latchman et al., 2001). At lowman et al., 2001; Okazaki et al., 2001). The PD-1 inhibi-
tory effects do not require the N-terminal tyrosine in the antigen concentrations, PD-L2:PD-1 interactions inhibit
strong B7-CD28 signals. In contrast, at high antigenITIM-like sequence but do require the other tyrosine
residue in the C-terminal tail. This tyrosine is phosphory- concentrations, PD-L2:PD-1 interactions reduce cyto-
kine production but do not inhibit T cell proliferation.lated and recruits src homology 2 domain-containing
tyrosine phosphatase 2 (SHP-2) on coligation of PD-1 Inhibition of T cell proliferation and cytokine produc-
tion by both resting and previously activated CD4 andwith the cell receptor. However, the exact molecular
target(s) of SHP-2 is not yet clear. PD-1 is highly glycosy- CD8 T cells, and even naive T cells from cord blood
have been observed using PD-L1Ig or PD-L2Ig fusionlated, and there is 60% amino acid identity between the
human and murine proteins (Finger et al., 1997; Shino- proteins together with anti-CD3-mAb (Carter et al., 2002;
Gao et al., 2003). In that setting, the proliferative re-hara et al., 1994). PD-1 is expressed by activated, but
not naive, CD4 and CD8 T cells, B cells, and myeloid sponses of wild-type, but not PD-1/, T cells were inhib-
ited by anti-CD3 plus PD-L1-Ig, indicating that the inhibi-cells (Agata et al., 1996) in contrast to the more restricted
expression of CD28 and CTLA-4 on naive and activated tory signal was transduced by PD-1.
Some reports indicate that PD ligands can “positively”T cells, respectively. After activation, PD-1 expression
peaks at day 3 and remains on the cell surface. costimulate T cell proliferation and cytokine production
(Dong et al., 1999; Tamura et al., 2003; Tseng et al.,The ligands for PD-1 are PD-L1 (B7H1) and PD-L2
(B7-DC). These ligands are members of the B7 family of 2001). The basis for this discrepancy is unclear but
raises the possibility that signaling through PD-1 canreceptors. PD-L1 is constitutively expressed on freshly
isolated splenic T cells, B cells, macrophages, and den- provide positive as well as negative signals. Whether
the putative positive signals are mediated by the yetdritic cells (DCs), and gets upregulated on T cells, mac-
rophages, and DCs after activation (Liang et al., 2003). unidentified second receptor/s other than PD-1 remains
unclear. By analogy to other CD28:B7 family of costimu-PD-L1 expression has also been detected in non-
lymphoid organs such as heart, placenta, lung, and pan- latory molecules, we would predict that a receptor medi-
ating a positive signal from PD ligands does exist. Char-creas in both human and mouse tissues (Liang et al.,
2003). In contrast, PD-L2 expression was only inducible acterization of the structure, expression, and function
of such a receptor is important for further analysis ofon macrophages and DCs after cytokine stimulation
(Yamazaki et al., 2002). The expression of PD-L1 and the roles of this pathway in regulating immune responses.
As discussed above, the inhibitory activity of PD-1 isPD-L2 is differentially regulated by Th1 and Th2 cyto-
kines, PD-L1 is highly expressed on inflammatory mac- dependent on association of the cytoplasmic tyrosine
phosphatase, SHP-2, with the ITSM, rather than the ITIMrophages and can be further upregulated by exposure
to lipopolysaccharide and IFN-. In contrast, PD-L2 is motif more typically associated with inhibitory signals
(Latchman et al., 2001; Okazaki et al., 2001). Involvementnot expressed on inflammatory macrophages but can
be induced by alternative activation via IL-4 (Loke and of the ITSM in PD-1-mediated inhibition is interesting
since, in the case of CD150, this motif has been shownAllison, 2003). Interestingly, PD-L1 is expressed on regu-
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to be able to bind to alternative downstream targets to experimental animal models (Table 1). In the spontane-
ous autoimmune diabetes model in NOD mice, PD-1affect either positive or negative signaling (Sharpe and
or PD-L1, but not PD-L2, blockade rapidly precipitatedFreeman, 2002; Shlapatska et al., 2001). Therefore, the
diabetes in prediabetic female NOD mice irrespectivedetection of another binding partner for the cytoplasmic
of age (from 1 to 10 weeks old), although it was mosttail of PD-1 might help explain the discrepant positive
pronounced in the older mice (Ansari et al., 2003). Bysignaling noted above.
contrast, CTLA-4 blockade induced disease only in neo-Ligation of PD-1 on T cells leads to cell cycle arrest
nates, consistent with previous reports in an NOD TCRin G0/G1 but does not increase cell death (Latchman et
transgenic mouse model of autoimmune diabetesal., 2001). Inhibition of T cell proliferation by PD-1:PD-L
(Luhder et al., 1998) and indicating that CTLA-4 regula-interaction is mediated by inhibition of IL-2 production
tion is restricted to the initial phase of disease in thisand affects both CD4 and CD8 subsets (Carter et al.,
model. Male NOD mice, typically resistant to develop-2002). These observations parallel those reported for
ment of diabetes, also developed disease followinginhibition of T cell activation and proliferation by regula-
PD-1:PD-L1 pathway blockade, but NOR mice, congeniction of IL-2 transcription (Brunner et al., 1999; Walunas et
to NOD but resistant to the development of diabetes,al., 1996). Blockade of the PD-1:PD-L pathway enhances
did not. Insulitis scores were significantly higher, andantigen-specific T cell expansion in response to immuni-
the frequency of IFN--producing GAD-reactive spleno-zation in vivo (Salama et al., 2003) and affects both Th1
cytes was increased following PD-1:PD-L1 pathwayand Th2 cells (Salama et al., 2003; B. Zhu and S.J.K.,
blockade as compared to controls. However, there wasunpublished data). Inhibition of PD-1 induced prolifera-
no increase in anti-insulin antibodies. Interestingly, PD-tion of effector T cells in the adenovirus-infected liver
L1, but not PD-L2, was expressed on inflamed islets ofand resulted in rapid clearance of the virus (Iwai et al.,
NOD mice. These data demonstrate a central role for2003).
PD-1:PD-L1 interaction in the regulation of inductionPD-1 is expressed by pro-B cells and may play a role
and progression of autoimmune diabetes in the NODin B cell differentiation (Finger et al., 1997). It is also
mouse. The data also suggest that perhaps local expres-expressed on the surface of activated B cells. The
sion of PD-L1 on islet cells plays a critical role in regulat-PD-1:PD-L pathway negatively regulates B cell prolifera-
ing attacking autoreactive T cells keeping the autoim-tion and differentiation including class switching or reg-
mune response in check (Ansari et al., 2003). Indeed,ulates T cell help for B cells, as evidenced by the in-
recent unpublished data from our group show that PD-crease in serum levels of IgG2b, IgA, and most strikingly
L1 blockade accelerates development of diabetes inIgG3, but not IgM and IgG1, in PD-1/ mice (Nishimura
multiple NOD congenic mouse strains that are resistantet al., 1998).
to diabetes and increases incidence of disease in somePD-1 and Autoimmune Responses
of these strains. However, a recent study showed thatThat PD-1 functions as a negative costimulatory recep-
transgenic expression of PD-L1 on islet cells resultedtor was initially suggested by studies in PD-1-deficient
in increased incidence (7%–14% by 3 weeks of age) ofmice that showed increased T and B cell proliferation,
diabetes in normal mice and accelerated rejection ofalbeit delayed as compared to CTLA-4 deficient mice,
islet grafts (Subudhi et al., 2004). In addition, PD-L1and predisposition to develop autoimmune diseases
expression increased CD8 T cell proliferation and pro-(Nishimura et al., 1998). Indeed, PD-1/ mice on the
moted autoimmunity induction in a T cell adoptive trans-C57BL/6 background develop lupus-like arthritis and glo-
fer model of diabetes. The results were attributed to amerulonephritis (Nishimura et al., 1999), while PD-1/
putative positive costimulatory signal provided bymice on the BALB/c background develop dilated cardio-
PD-L1 interaction with a receptor on T cells other thanmyopathy (Nishimura et al., 2001), which appears to be
PD-1 (Subudhi et al., 2004). The effect of transgenicmediated by autoantibodies to cardiac proteins (Oka-
(constitutive or induced) expression of PD-L1 on islets
zaki et al., 2003). These data also suggest that the ge-
of autoimmune-prone NOD mice has not been investi-
netic background of the strain influences the phenotype
gated, however. Therefore, one may argue that the tim-
of the PD-1/ mice. The phenotype of PD-L2-deficient ing and locale of expression of PD-1 ligands are critical
mice was reported to be normal up to one year of age determinants of the type of signal that will be transduced
without evidence of autoimmunity or immunopathology to the T cell. It is also interesting to hypothesize that
(Shin et al., 2003). PD-L1-deficient mice appear normal when PD-L1 is expressed in the context of inflammation,
except for intrahepatic accumulation of CD8 T cells it interacts with PD-1, leading to regulation of the im-
(Dong et al., 2004). Further analyses of the phenotype of mune response in the tissue, but when PD-L1 is constitu-
these mice, including the phenotype of double-deficient tively expressed it may interact with the putative positive
mice for both PD-L1 and PD-L2, in various models of receptor, thus enhancing the immune response (Figure
autoimmunity should be very informative. In the NOD 2). Taken together, the studies summarized above high-
mouse for example, we would predict that PD-L1-defi- light the complex functions of the PD-L1 pathway in
cient mice will have earlier onset, and more severe dia- regulating autoimmune diabetes. Indeed, even if one
betes associated with expansion of autoreactive T cells accepts that PD-L1 is exclusively a regulatory pathway
in vivo. In an autoimmune disease induced by immuniza- in the setting of autoimmune diabetes, it is clear that
tion with antigen, the phenotype may depend on the regulation fails in NOD mice (and presumably humans
strain of mice and the natural tissue expression patterns with type I diabetes) since they ultimately develop dis-
of the ligands during the course of the disease. ease. Therefore, understanding the mechanisms of co-
The functions of the PD-1 and its ligands in regulating stimulation mediated by PD-L1 is critical for development
of novel therapies to reestablish tolerance in humans.autoimmune diseases have been investigated in several
Review
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Table 1. In Vivo Autoimmune Disease Models Targeting the PD-1:PD-L Pathway
Model Manipulation Outcome In Vitro Reference
EAE anti-PD-1 worse disease increased MOG-specific Salama et al., 2003
IFN--producing cells
EAE anti-PD-L1 no effect Salama et al., 2003
EAE anti-PD-L2 worse disease Salama et al., 2003
NOD anti-PD-1 earlier onset of diabetes increased frequency of GAD- Ansari et al., 2003
specific IFN--producing cells
NOD anti-PD-L1 earlier onset of diabetes increased frequency of GAD- Ansari et al., 2003
specific IFN--producing cells
NOD anti-PD-L2 no effect
CD4CD45RB(high)- anti-PD-L1 suppress disease reduced production of Th1 Kanai et al., 2003
induced colitis cytokines by lamina propria
CD4 T cells
CD4CD45RB(high)- anti-PD-L2 no effect
induced colitis
Transgenic expression increased incidence increased CD8 T cell Subudhi et al., 2004
of PD-L1 on islets of diabetes proliferation
Transplantation of increased rejection increased CD8 T cell Subudhi et al., 2004
PD-L1 transgenic proliferation
islets
PD-1/ C57/BL6 background lupus-like disease Nishimura et al., 1999
PD-1/ BALB/c background cardiomyopathy Okazaki et al., 2003
In an antigen-induced autoimmune disease model on the strain of mice studied. Whether these differences
reflect bone marrow-derived APC versus tissue expres-PD-1-negative signaling also appears to regulate im-
mune responses in vivo (Salama et al., 2003). In the sion patterns of PD-1 ligands in the various strains re-
mains to be determined.experimental autoimmune encephalomyelitis model (EAE)
in C57BL/6 mice where disease was induced by immuni- We also investigated the effect of PD-L blockade on
the course of EAE in NOD mice after PLP immunizationzation with myelin oligodendrocyte glycoprotein (MOG),
the mice developed accelerated and more severe dis- (I. Guleria, S.J.K. and M.H.S., unpublished data). Inter-
estingly, PD-L1 or PD-L2 blockade worsened EAE butease after PD-1 blockade. This was associated with
increased inflammatory cell infiltration in the brain. only PD-L1 blockade precipitated early diabetes caus-
ing two autoimmune diseases at the same time. In aWorsening of disease following PD-1 blockade was also
associated with a heightened autoimmune response to recent collaboration with Bluestone’s group, we tested
the effect of PD-L1 blockade in B7-2-deficient NOD miceMOG, manifested by increased frequency of IFN--pro-
ducing T cells, increased delayed-type hypersensitivity that have a defect in early activation of diabetic reper-
toire and are protected from diabetes but develop pe-responses, and higher serum levels of anti-MOG anti-
bodies. Interestingly, and in contrast to the spontaneous ripheral neuropathy (Salomon et al., 2001). The mice did
not develop diabetes after PD-L1 blockade but had moreautoimmune diabetes model in NOD mice, PD-L2, but
not PD-L1, blockade also resulted in disease augmen- severe peripheral neuropathy suggesting that PD-L1
blockade is acting late and expanding a selective auto-tation (Salama et al., 2003). This is in spite of early and
persistent upregulation of PD-L1 and only little and de- reactive T cell repertoire (H. Bour-Jordan, I. Guleria,
M.H.S., and J. Bluestone, unpublished data).layed expression of PD-L2 in the central nervous system
during the course of EAE. Moreover, treatment with a Unexpectedly, and perhaps consistent with a possible
positive costimulatory function of PD-L1 signaling, in ablocking anti-PD-L1 mAb, even late in the course of
EAE, does not worsen disease in C57BL/6 mice (B. Zhu, colitis model induced by transfer of CD4CD45RB (high)
T cells, administration of anti-PD-L1, but not anti-PD-M.H.S. and S.J.K., unpublished data). These data are
similar to what was observed in an asthma model, where L2, antibodies suppressed wasting disease with colitis,
abrogated leukocyte infiltration, and reduced the pro-PD-L1, but not PD-L2, was abundantly expressed in the
lungs and blockade of PD-L2 worsened disease (Matsu- duction of Th1, but not Th2, cytokines by lamina propria
CD4 T cells. These data suggest a role for PD-L1 inmoto et al., 2004). What is the function of the PD-L1
expressed in the tissues in these models then? The intestinal mucosal inflammation, possibly through inter-
action with an as yet unidentified receptor for PD-L1expression of PD-L1 in the central nervous system of
EAE mice is concentrated around the cellular infiltrates; in inducing local T cell activation (Kanai et al., 2003);
alternatively, anti-PD-L1 could be depleting cells thatsome of the PD-L1 is possibly expressed by the infiltrat-
ing cells, perhaps a population of regulatory cells. We express PD-L1 at high levels.
Limited studies in humans with autoimmune diseasesare in the process of generating mice with transgenic
expression of PD-L1 or PD-L2 on astrocytes to explore also suggest a potential regulatory function of PD-1. In
patients with rheumatoid arthritis, synovial fluid exami-the functions of these ligands in the central nervous
system. More recently, unpublished data from our group nation showed increased expression of PD-1 predomi-
nantly on CD4 T cells. CD4 PD-1 T cells were mostlyalso show that PD-1:PD-L1/L2 blockade worsens EAE
in otherwise normally resistant mouse strains, and that CTLA-4 positive and CD26 negative, were enriched in
CD45RB (low) cells, and produced IL-10 (Hatachi et al.,PD-L1 and PD-L2 have differential functions depending
Immunity
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2003). A recent study of patients with systemic lupus bodies (Suh et al., 2003). Further studies are required
to identify the exact receptor/receptors and define theerythematosis (SLE) showed an association of an in-
tronic SNP of PD-1 with development of SLE in Europe- functions of this pathway in immune responses.
B7H4 (B7x, B7S1) is another member of the B7 familyans (relative risk  2.6) and Mexicans (relative risk 
3.5). The associated allele of this SNP alters a binding that is a negative regulator of CD4 and CD8 T cells and
B cells. Expression of mRNA is widespread in humansite for the runt-related transcription factor 1 (RUNX1,
also called AML1) located in an intronic enhancer (Pro- tissues (spleen, lung, liver, thymus, placenta, testis,
skeletal muscle, ovary, pancreas, and small intestine)kunina et al., 2002). A relatively small study of type 1
diabetic patients also showed that the same SNP was but is not expressed as a protein (absent staining) in
normal tissues. In contrast, up to 85% of ovarian cancerassociated with increased risk of disease (Nielsen et al.,
2003). In collaboration with She et al., we are studying and 31% of lung cancer tissues constitutively express
B7H4, suggesting a tight regulation of B7H4 expressionthis issue further in patients and families with type I dia-
betes. at the translational level in normal peripheral tissues and
a potential role of B7H4 in the evasion of tumor immunityFinally, the interactions of PD-1 with other positive
and negative T cell costimulatory pathways in regulating (Choi et al., 2003). The expression of B7H4 is inducible
on hematopoeitic cells; monocyte-derived dendriticautoimmune disease are not fully understood. In the
EAE model described above, PD-1 blockade also accel- cells do not have the mRNA although they express
B7H4 after activation. Administration of B7H4Ig impairserated disease in the CD28-deficient animals that are
normally protected from disease (Chitnis et al., 2001; antigen-specific T cell responses in mice, while block-
ade of endogenous B7H4 by specific monoclonal anti-Salama et al., 2003). These results indicate that the PD-1
pathway is functional even in the absence of CD28 body promotes T cell responses (Sica et al., 2003).
B7H4Ig inhibits TCR-mediated proliferation and causescostimulation. Interestingly, in the CD28-deficient mice,
PD-1 blockade induced worse disease than CTLA-4 cell cycle arrest. It also inhibits maturation and effector
function of CD8 cytotoxic T lymphocytes (Sica et al.,blockade (Chitnis et al., 2001; Salama et al., 2003). While
the kinetics of upregulation of CTLA-4 and PD-1 are 2003). BTLA was proposed as the receptor for B7H4
based on indirect evidence of B7H4 binding to WT, butvery similar, the distinct expression patterns of their
respective ligands, B7-1 and B7-2 (mainly on profes- not BTLA/, cells. It is possible, however, that BTLA
regulates the expression of the B7H4 receptor. BTLA issional APCs) and PD-L1 and PD-L2 (on both professional
and non-professional APCs) suggest that the CTLA-4 not expressed by naive T cells but is induced during
activation and remains expressed on Th1, but not Th2,and PD-1 pathways may have complementary roles in
regulating immune responses. In the transplant setting cells (Watanabe et al., 2003). Similar to PD-1, crosslink-
ing BTLA with antigen receptors induces its tyrosinePD-1 signaling by PD-L1Ig promoted prolonged graft
survival in CD28-deficient recipients (Ozkaynak et al., phosphorylation and association with the Src homology
domain 2 (SH2)-containing protein tyrosine phospha-2002) and, when combined with anti-CD154 mAb (Gao
et al., 2003), in mice. tases SHP-1 and SHP-2, and attenuates production of
IL-2. BTLA-deficient T cells show increased prolifera-
tion, and BTLA-deficient mice have increased specificB7H3 and B7H4
antibody responses and enhanced sensitivity to EAEB7H3 is another member of the B7 family that shares
(Watanabe et al., 2003).20%–27% amino acid identity with other B7 family mem-
bers. B7H3 mRNA is not detectable in peripheral blood
mononuclear cells, although it is found in various normal ICOS as a Negative Regulatory Pathway?
ICOS is an inducible costimulatory receptor expressedtissues and in several tumor cell lines (Chapoval et al.,
2001; Sun et al., 2002). Expression of B7H3 can be in- by activated T cells and by resting memory cells (Hutloff
et al., 1999; Yoshinaga et al., 1999). This pathway regu-duced on dendritic cells and monocytes by inflammatory
cytokines and a combination of phorbol myristate ace- lates Th-dependent antibody production and Th1 and
Th2 cytokine responses in mouse models (Carreno andtate plus ionomycin. Soluble B7H3 protein binds a puta-
tive yet unidentified counterreceptor on activated T cells Collins, 2002), but under some circumstances it more
effectively costimulates Th2 responses (McAdam et al.,that is distinct from CD28, CTLA-4, inducible ICOS, and
PD-1 (Chapoval et al., 2001). There is still controversy 2000; Wang et al., 2000). ICOS also costimulates the
immunoregulatory cytokine IL-10 (Akbari et al., 2002;as to the exact costimulatory functions of B7H3. It has
been reported to costimulate proliferation of both CD4 Wang et al., 2000). Blockade of the ICOS pathway can
affect both primary Th1 and Th2 responses, but highlyand CD8 T cells, enhance the induction of cytotoxic
T cells, and selectively stimulate IFN- production in the polarized Th2 responses may be more affected by ICOS
blockade (Coyle et al., 2000). B7h (B7RP-1, B7H2,presence of T cell receptor signaling; purified T cells
stimulated with anti-CD3 had a selective increase in LICOS, ICOSL) is the ligand for ICOS. B7h is expressed
constitutively by APCs, such as B cells and macro-IFN- mRNA in the presence of B7H3Ig. In a model of
EL-4 lymphoma, intratumoral injection of a mouse B7H3 phages, and can be induced in nonlymphoid tissues by
inflammatory stimuli. Most of the evidence suggestspcDNA3 expression plasmid led to complete regression
of 50% tumors, a response that was dependent on CD8 that ICOS-B7h is a positive costimulatory pathway for
activated T cells, but three pieces of evidence indicateT cells and NK cells (Sun et al., 2003). Yet another report
indicated a negative T cell costimulatory function of Th1 that it may function as a regulatory pathway in autoim-
munity and allergy. In the EAE model, ICOS-deficientimmune responses and showed that B7H3/ mice have
earlier onset of EAE and develop anti-DNA autoanti- mice and early blockade at time of immunization
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worsened disease, presumably due to Th1 polarization blockade worsens induction and progression of autoim-
mune responses. Thus, one may hypothesize that nega-(McAdam et al., 2001; Rottman et al., 2001). In an airway
hyperreactivity model, ICOS has been shown to be im- tive signaling by the PD-1:PD-L pathway is the gate-
keeper for the local immune health in the tissues. Thisportant in T cell regulatory function to inhibit Th2 re-
sponses (Akbari et al., 2002; Coyle et al., 2000). Finally, is supported by the findings that blockade of PD-1 or
PD-1 deficiency appears more strain specific, with dif-while ICOS-deficient mice and ICOS-B7h blockade pro-
long allograft survival in a fully allogeneic mouse cardiac ferent tissues targeted by the unregulated immune re-
sponse in different strains.transplant model, early ICOS blockade accelerated allo-
graft rejection in a minor mismatched model. The differ- Second, what are the functions of the various negative
pathways in regulating CD4 versus CD8 T cells, Th1ent outcome between the two models may be due to
the fact that in a minor mismatch model the frequency versus Th2 responses, and activated versus effector/
memory cells in the context of autoimmune responses?of alloreactive T cells is usually low, and Th1 switching
has been associated with worse graft survival (Harada The answers to these questions are unknown but under
intense investigations by several groups. Understandinget al., 2003; Sho et al., 2002).
these functions is critical since it may explain the appar-
ently confusing or unexpected results of pathway block-Summary
ade in various strains and models.With the sequencing of the human genome, hundreds
Third, under what circumstances do some of theseof new genes have been identified. Among those are
receptors provide positive costimulation? In the case ofnew receptor ligands for T cell costimulatory pathways.
PD-1 ligands it does appear that positive costimulationNew B7 family of receptors have been reported: some
may be mediated through a yet unidentified receptorwith positive costimulatory capacity, some with a role
other than PD-1. Under physiologic conditions, the ICOS-in down-regulating immune responses, yet others may
B7h pathway primarily functions to positively costimu-have dual functions. For some of these pathways such
late activated T cells and in some circumstances prefer-as B7H3, very little is known, but even for those path-
entially costimulates Th2 cells. Thus, in autoimmuneways that have been extensively studied such as the
models where Th2 cells are protective, ICOS deficiencyCD28/CTLA-4:B7 and PD-1:PD-L1/PD-L2 pathway, new
or early blockade is detrimental while late blockade pro-insights are still being generated. The intricacies of con-
tects from Th1-mediated autoimmunity. Therefore, thetrolling T cell activation are enhanced by the complexity
timing/stage and phenotype of the immune responseof the costimulatory pathways, such that there are multi-
are critical determinants of the functions of some of theple possible receptor-ligand interactions. This is also
costimulatory pathways in vivo.complicated by the expression patterns and locale of
Fourth, what are the roles of the negative T cell costi-the receptor-ligand pairs on APCs versus tissues and
mulatory pathways in promoting generation or effectorthe complex interactions among the various pathways.
function of regulatory T cells. Undoubtedly, these vari-In summary, there are multiple negative T cell costimu-
ous roles have important implications for the outcomelatory signaling pathways; some have dual functions
of the immune response, and the net effect of deficiencyproviding positive signals at times. However, several
or blockade may be dependent on the balance betweenquestions remain to be answered. First, are these path-
the various roles of these pathways on autoreactive ver-ways merely redundant whereby one pathway takes
sus regulatory T cells in vivo.over the functions of another in case of absence of
Finally, the exact in vivo roles of B7H3 and B7H4 in theblockade, or is there some level of hierarchy? How does
context of the hierarchal scheme of negative regulatorythis hierarchy relate to T cell/APC versus parenchymal
pathways requires further investigation, although fromexpression patterns of the ligands (Figures 1 and 2)?
the standpoint of expression and function, these path-Careful examination of the data show that there is likely
way appear to be more like the PD-1:PD-L pathwaya level of hierarchy and the functions of the various
rather CTLA-4. Understanding the mechanisms of T cellpathways are complementary in many respects, al-
activation/inhibition through costimulation opens a newthough some redundancy does exist probably to protect
window of opportunities into therapeutic interventionsthe organism from unwanted immune responses. It is
for autoimmune disease, transplantation, tumor control,clear that the CTLA-4 pathway appears to be the domi-
asthma/allergy, and infection control/vaccine develop-nant-negative T cell costimulatory pathway within the
ment.lymphoid organs. This is evident by the phenotype of
the CTLA-4 gene knockout mice that die from severe
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